68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

Other illness

• Lung cancer that can not be resected or has distant metastasis, or for other reasons can not tolerate surgery;
• Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colorectal, endometrial, cervical, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period;
• Any active or history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. The subjects were innate or acquired immunodeficiency (such as HIV), or active hepatitis (hepatitis B reference: HBsAg) positive; Hepatitis C reference: HCV antibody positive;
• Having a history of severe cardiovascular disease, severe myelosuppression and severe hepatic and renal insufficiency. Having a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
• Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.

Lab values

• Uncontrolled diabetes or fasting blood glucose ≥11.0 mmol/L on the day of the test;

Other

• Histologically confirmed were NOT NSCLC;
• Women who are or may become pregnant, and lactating women are excluded;

• Pre-treatment stage as clinical IB-IIIA (AJCC/UICC 8th Edition);
• Curative resectability has to be explicitly verified by the experienced surgical investigator;
• Histologically confirmed diagnosis of primary non-small lung cancer.
• Men and women aged 18 Years to 75 Years;
• Eastern Cooperative Oncology Group (ECOG) performance status: 0-1;
• expected survival ≥ 6 months;
• Sign on the informed consent form (ICF).